ACM
EPRX

Aisling Capital Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Aisling Capital Management’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.15M Hold
325,000
– – 0.46% 11
2026
Q1 		$2.35M Buy
+325,000
New +$2.62M 0.49% 9

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Aisling Capital Management's EPRX Position: Q2 2026 in Review

Aisling Capital Management held its Eupraxia Pharmaceuticals (EPRX) position steady in Q2 2026 at 325,000 shares worth $2.15M. The position accounts for 0.46% of the portfolio, ranked #11.

Aisling Capital Management first reported a position in EPRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.35M in Q1 2026. 68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Aisling Capital Management held 325,000 shares of Eupraxia Pharmaceuticals worth $2.15M as of Q2 2026.
  • Aisling Capital Management left its Eupraxia Pharmaceuticals share count unchanged in Q2 2026.
  • Eupraxia Pharmaceuticals made up 0.46% of Aisling Capital Management's portfolio in Q2 2026, its #11 holding.
  • Aisling Capital Management first reported a position in Eupraxia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Aisling Capital Management's Eupraxia Pharmaceuticals position peaked at $2.35M in Q1 2026.
  • 68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Aisling Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.